IR Insights: Highlighting Progress and Strategic Priorities at R&D Day
At our annual R&D Day, Moderna announced program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline.
Just after programming wrapped, Moderna’s CEO Stephane Bancel, President Stephen Hoge and CFO Jamey Mock sat down in New York to discuss their focus on delivering 10 new products to patients, pacing R&D investment, and building the Company’s commercial business. Watch our latest IR Insights video below:
Forward-Looking Statements
This post and accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s focus on ten product approvals through 2027; Moderna’s expected regulatory submissions in 2024 and the potential timing of regulatory approvals; the rate of success of Moderna's platform; Moderna's ability to drive vaccination coverage rates; Moderna’s ability to execute on its commercial strategy; Moderna’s ability to execute on its capital allocation strategy; Moderna's financial framework through 2028, its ability to reduce R&D expenses and its anticipated revenue growth; Moderna’s expectations for its respiratory franchise; and expected timing for Moderna to break even on an operating cash cost basis. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.